Literature DB >> 33707471

Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors.

Yasuhiro Koh1, Tomoya Kawaguchi2,3, Motohiro Izumi4,5, Jun Oyanagi5, Kenji Sawa4, Mitsuru Fukui6, Koichi Ogawa4, Yoshiya Matsumoto4, Yoko Tani7, Tomohiro Suzumura7, Tetsuya Watanabe4, Hiroyasu Kaneda7, Shigeki Mitsuoka7, Kazuhisa Asai4, Masahiko Ohsawa8, Nobuyuki Yamamoto5.   

Abstract

Multiple primary lung cancers (MPLCs) harbour various genetic profiles among the tumours, even from individuals with same non-intrinsic risk factors. Paired mutational analyses were performed to obtain a census of mutational events in MPLC and assess their relationship with non-intrinsic risk factors. Thirty-eight surgical specimens from 17 patients diagnosed as MPLC were used. Extracted DNAs were sequenced for somatic mutations in 409 cancer-associated genes from a comprehensive cancer panel. We statistically analysed the correlation between each driver mutation frequency and non-intrinsic risk factors using Fisher's exact test, and whether genetic mutations occurred concomitantly or randomly in MPLC using an exact test. Comprehensive genetic analyses suggested different mutation profiles in tumours within the same individuals, with some exceptions. EGFR, KRAS, TP53, or PARP1 mutations were concomitantly detected in some MPLC cases. EGFR mutations were significantly more frequent in never or light smokers and females. Concomitant EGFR or KRAS mutations in MPLCs were significantly more frequent than expected by chance (P = .0023 and .0049, respectively) suggesting a more prominent role of non-intrinsic risk factors in EGFR and KRAS mutations than other mutations, which occurred more randomly. Concomitant EGFR or KRAS mutations were particularly prominent in never or light smokers and males.

Entities:  

Mesh:

Year:  2021        PMID: 33707471      PMCID: PMC7952588          DOI: 10.1038/s41598-021-83609-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  38 in total

1.  Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Authors:  Andrew G Nicholson; Kathleen Torkko; Patrizia Viola; Edwina Duhig; Kim Geisinger; Alain C Borczuk; Kenzo Hiroshima; Ming S Tsao; Arne Warth; Sylvie Lantuejoul; Prudence A Russell; Erik Thunnissen; Alberto Marchevsky; Mari Mino-Kenudson; Mary Beth Beasley; Johan Botling; Sanja Dacic; Yasushi Yatabe; Masayuki Noguchi; William D Travis; Keith Kerr; Fred R Hirsch; Lucian R Chirieac; Ignacio I Wistuba; Andre Moreira; Jin-Haeng Chung; Teh Ying Chou; Lukas Bubendorf; Gang Chen; Giuseppe Pelosi; Claudia Poleri; Frank C Detterbeck; Wilbur A Franklin
Journal:  J Thorac Oncol       Date:  2017-11-07       Impact factor: 15.609

2.  Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.

Authors:  Snehal B Patel; Wendy Kadi; Ann E Walts; Alberto M Marchevsky; Andy Pao; Angela Aguiluz; Tudor Mudalige; Zhenqui Liu; Nan Deng; Jean Lopategui
Journal:  J Mol Diagn       Date:  2017-09-01       Impact factor: 5.568

3.  Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.

Authors:  Nicolas Girard; Charuhas Deshpande; Christopher Lau; David Finley; Valerie Rusch; William Pao; William D Travis
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

4.  Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma.

Authors:  Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Kyung Soo Lee; Kwhanmien Kim
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609

5.  EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.

Authors:  Shi-Xu Jiang; Kazuya Yamashita; Michiko Yamamoto; Chun-Ji Piao; Atsuko Umezawa; Makoto Saegusa; Tsutomu Yoshida; Masato Katagiri; Noriyuki Masuda; Kazushige Hayakawa; Isao Okayasu
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

6.  Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer.

Authors:  Ludmila Prudkin; Ximing Tang; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

7.  Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Authors:  Yoshiya Matsumoto; Kenji Sawa; Mitsuru Fukui; Jun Oyanagi; Naoki Yoshimoto; Tomohiro Suzumura; Tetsuya Watanabe; Hiroyasu Kaneda; Shigeki Mitsuoka; Kazuhisa Asai; Tatsuo Kimura; Nobuyuki Yamamoto; Kazuto Hirata; Yasuhiro Koh; Tomoya Kawaguchi
Journal:  Lung Cancer       Date:  2019-11-02       Impact factor: 5.705

8.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.

Authors:  Kazuya Taniguchi; Jiro Okami; Ken Kodama; Masahiko Higashiyama; Kikuya Kato
Journal:  Cancer Sci       Date:  2008-03-04       Impact factor: 6.716

9.  Predictors of outcomes after surgical treatment of synchronous primary lung cancers.

Authors:  David J Finley; Akihiko Yoshizawa; William Travis; Qin Zhou; Venkatraman E Seshan; Manjit S Bains; Raja M Flores; Nabil Rizk; Valerie W Rusch; Bernard J Park
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609

Review 10.  Evaluating intrinsic and non-intrinsic cancer risk factors.

Authors:  Song Wu; Wei Zhu; Patricia Thompson; Yusuf A Hannun
Journal:  Nat Commun       Date:  2018-08-28       Impact factor: 14.919

View more
  4 in total

Review 1.  Hydrogels and Hydrogel Nanocomposites: Enhancing Healthcare through Human and Environmental Treatment.

Authors:  Angela M Gutierrez; Erin Molly Frazar; Maria Victoria X Klaus; Pranto Paul; J Zach Hilt
Journal:  Adv Healthc Mater       Date:  2021-12-11       Impact factor: 9.933

2.  Identification of lung cancer drivers by comparison of the observed and the expected numbers of missense and nonsense mutations in individual human genes.

Authors:  Olga Y Gorlova; Marek Kimmel; Spiridon Tsavachidis; Christopher I Amos; Ivan P Gorlov
Journal:  Oncotarget       Date:  2022-05-25

3.  Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer.

Authors:  Bin Huang; Quan Chen; Derek Allison; Riham El Khouli; Keng Hee Peh; James Mobley; Abigail Anderson; Eric B Durbin; Donald Goodin; John L Villano; Rachel W Miller; Susanne M Arnold; Jill M Kolesar
Journal:  JCO Precis Oncol       Date:  2021-09-29

4.  Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers.

Authors:  Wen-Ru Chou; Ben-Chang Shia; Yen-Chun Huang; Chieh-Wen Ho; Mingchih Chen
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.